<DOC>
	<DOCNO>NCT00004033</DOCNO>
	<brief_summary>RATIONALE : Patient abstract available PURPOSE : Patient abstract available</brief_summary>
	<brief_title>Liposomal-Cisplatin Analogue ( L-NDDP ) Treating Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor efficacy liposomal-cisplatin analogue ( L-NDDP ) administer pleural space patient malignant pleural mesothelioma . II . Determine time progression overall survival patient population . III . Evaluate quantitative qualitative toxicity intrapleural L-NDDP . OUTLINE : All patient undergo thoracoscopy general anesthesia . The thoracoscope remove collect fluid drain chest cavity . The first treatment liposomal-cisplatin analogue ( L-NDDP ) administer time intrapleural space 10 minute period . Subsequent 10 minute intrapleural infusion L-NDDP percutaneous catheter administer every 3 week . Treatment continue unless unacceptable toxic effect disease progression occur . Antitumor activity assess 2 month second course therapy , every 2 month thereafter . PROJECTED ACCRUAL : A total 14-30 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm malignant pleural mesothelioma Free flow pleural effusion PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : WBC great 4,000/mm3 Granulocyte count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGPT great 1.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No unstable angina No clinical evidence congestive heart failure Pulmonary : No postobstructive pneumonia Other : Fertile patient must use effective contraception Not pregnant nursing No serious concurrent infection No prior malignancy except basal cell squamous cell skin carcinoma , stage I colon , cervical , breast , prostate , head neck , lung cancer , long evidence tumor occurrence within past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 3 week since prior hormonal therapy No concurrent hormonal therapy Radiotherapy : No prior chest radiotherapy At least 3 week since prior radiotherapy No concurrent radiotherapy Surgery : Prior pleurodesis chest surgery side effusion allow long free flow pleural effusion without loculation At least 2 week since major surgery biopsy Other : At least 3 week since use investigational medication No concurrent use investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>